A new drug combo may shield kidney transplant patients from a common viral threat

NCT ID NCT02328963

Completed Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial compares two immunosuppressive regimens in CMV-positive kidney transplant recipients. One group receives everolimus with a reduced dose of cyclosporine A, while the other gets standard mycophenolic acid with full-dose cyclosporine. The goal is to see whether the everolimus-based regimen can prevent CMV infection and graft loss as effectively as the standard approach, while potentially lowering infection rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: everolimus and reduced-dose cyclosporine A
What this could lead to: If successful, this approach could reduce the risk of CMV infection after kidney transplant while maintaining effective rejection prevention.
What could go wrong: This is a phase 4 study with a moderate sample size; results may not apply to all transplant recipients, and the regimen carries risks of side effects like infection or kidney toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease disease related to transplantation end stage renal failure cytomegalovirus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYTOMEGALOVIRUS INFECTION TRANSPLANTATION INFECTION

Contacts and locations

Locations

APHP - Hôpital Necker

Paris, 75015, France
APHP - Kremlin Bicetre

Paris, 94275, France
CHRU Caen - Hôpital de Caen

Caen, 14033, France
CHRU Strasbourg

Strasbourg, France
CHU La Cavale Blanche

Brest, 29609, France
CHU de Bordeaux

Bordeaux, 33000, France
CHU de Limoges - Hôpital Dupuytren

Limoges, France
CHU de Toulouse - Hôpital Rangueil

Toulouse, 31000, France
Hôpital Edouard Herriot

Lyon, 69003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.